Two Directors at Carvana Co sold 144,516 shares at between 115.362USD and 117.330USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. “Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatmen...
Moody's Ratings (Moody's) affirmed the B2 corporate family rating (CFR) and B2-PD probability of default rating (PDR) of Cogent Communications Group, Inc. (Cogent or Cogent Communications Group), a multinational Tier 1 internet service provider, following the announcement that Cogent IPv4 Holdco LLC...
MIAMI--(BUSINESS WIRE)-- Element Solutions Inc (NYSE:ESI) (“Element Solutions” or the “Company”), a global and diversified specialty chemicals company, today announced its financial results for the three months ended March 31, 2024. Executive Commentary President and Chief Executive Officer Benjamin Gliklich commented, “Element Solutions executed well this quarter in recovering electronics markets. Our ongoing investment in high-value technologies, particularly in advanced packaging and semiconductor markets, has driven favorable mix, while the carryover of our pricing actions against defl...
MIAMI--(BUSINESS WIRE)-- Element Solutions Inc (NYSE:ESI) ("Element Solutions") announced today that it intends to release its 2024 first quarter financial results after the market close on Monday, April 29th, 2024. Element Solutions will host a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Tuesday, April 30th, 2024. Participants on the call will include Executive Chairman Sir Martin E. Franklin, Chief Executive Officer Benjamin Gliklich and Chief Financial Officer Carey J. Dorman. To listen to the call by telephone, please dial 888-510-234...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR). Miranda Toledano...
MIAMI--(BUSINESS WIRE)-- Element Solutions Inc (NYSE:ESI) announced today that Benjamin Gliklich, President and Chief Executive Officer, and leaders from its Electronics segment are scheduled to present and participate in a Q&A session hosted by Chemicals analyst Duffy Fisher and Semiconductor analyst Toshiya Hari of Goldman Sachs on Wednesday, April 3, 2024 at 10:00 a.m. ET. The discussion will center on Element Solutions’ participation as a provider of enabling solutions for emerging technologies. Dial-in details for the conference call and copies of the slides related to the presentation ...
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.